Free Trial
NASDAQ:ZURA

Zura Bio Q4 2024 Earnings Report

Zura Bio logo
$1.37 -0.07 (-4.86%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.00 (+0.36%)
As of 04/25/2025 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Zura Bio Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zura Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zura Bio's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Earnings Documents

Zura Bio Earnings Headlines

Head-To-Head Comparison: Zura Bio (ZURA) & The Competition
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Comparing Zura Bio (ZURA) and Its Rivals
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA), a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

View Zura Bio Profile

More Earnings Resources from MarketBeat